Yoshino K, Kurita T, Takahashi F et al (2023) Annual report of the Committee on Gynecologic Oncology, the Japan Society of Obstetrics and Gynecology: Annual Patient Report for 2020 and Annual Treatment Report for 2015. J Obstet Gynaecol Res 49:2584–2592. https://doi.org/10.1111/jog.15767

Article  PubMed  Google Scholar 

Albert A, Lee A, Allbright R et al (2020) Primary sarcoma of the cervix: an analysis of patient and tumor characteristics, treatment patterns, and outcomes. J Gynecol Oncol 31:e25. https://doi.org/10.3802/jgo.2020.31.e25

Article  PubMed  Google Scholar 

Kimyon Comert G, Turkmen O, Karalok A et al (2017) Therapy modalities, prognostic factors, and outcome of the primary cervical carcinosarcoma: meta-analysis of extremely rare tumor of cervix. Int J Gynecol Cancer 27:1957–1969. https://doi.org/10.1097/igc.0000000000001086

Article  PubMed  Google Scholar 

Querleu D, Morrow CP (2008) Classification of radical hysterectomy. Lancet Oncol 9:297–303. https://doi.org/10.1016/s1470-2045(08)70074-3

Article  PubMed  Google Scholar 

Sharma C, Deutsch I, Horowitz DP et al (2012) Patterns of care and treatment outcomes for elderly women with cervical cancer. Cancer 118:3618–3626. https://doi.org/10.1002/cncr.26589

Article  PubMed  Google Scholar 

Shimamoto K, Saito T, Kitade S et al (2018) A study of treatments and outcomes in elderly women with cervical cancer. Eur J Obstet Gynecol Reprod Biol 228:174–179. https://doi.org/10.1016/j.ejogrb.2018.06.032

Article  PubMed  Google Scholar 

Cremona CA, Behrens A (2014) ATM signalling and cancer. Oncogene 33:3351–3360. https://doi.org/10.1038/onc.2013.275

Article  CAS  PubMed  Google Scholar 

Gotoh O, Sugiyama Y, Takazawa Y et al (2019) Clinically relevant molecular subtypes and genomic alteration-independent differentiation in gynecologic carcinosarcoma. Nat Commun 10:4965. https://doi.org/10.1038/s41467-019-12985-x

Article  CAS  PubMed  PubMed Central  Google Scholar 

Michels J, Vitale I, Saparbaev M et al (2014) Predictive biomarkers for cancer therapy with PARP inhibitors. Oncogene 33:3894–3907. https://doi.org/10.1038/onc.2013.352

Article  CAS  PubMed  Google Scholar 

Hussain M, Mateo J, Fizazi K et al (2020) Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer. N Engl J Med 383:2345–2357. https://doi.org/10.1056/NEJMoa2022485

Article  CAS  PubMed  Google Scholar 

Chi KN, Sandhu S, Smith MR et al (2023) Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial. Ann Oncol 34:772–782. https://doi.org/10.1016/j.annonc.2023.06.009

Article  CAS  PubMed  Google Scholar 

Fizazi K, Azad AA, Matsubara N et al (2024) First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial. Nat Med 30:257–264. https://doi.org/10.1038/s41591-023-02704-x

Article  CAS  PubMed  Google Scholar 

Bang YJ, Xu RH, Chin K et al (2017) Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 18:1637–1651. https://doi.org/10.1016/s1470-2045(17)30682-4

Article  CAS  PubMed  Google Scholar 

Tung NM, Robson ME, Ventz S et al (2020) TBCRC 048: Phase II study of olaparib for metastatic breast cancer and mutations in homologous recombination-related genes. J Clin Oncol 38:4274–4282. https://doi.org/10.1200/jco.20.02151

Article  CAS  PubMed  Google Scholar 

Javle M, Shacham-Shmueli E, Xiao L et al (2021) Olaparib Monotherapy for Previously Treated Pancreatic Cancer With DNA Damage Repair Genetic Alterations Other Than Germline BRCA Variants: Findings From 2 Phase 2 Nonrandomized Clinical Trials. JAMA Oncol 7:693–699. https://doi.org/10.1001/jamaoncol.2021.0006

Article  PubMed  PubMed Central  Google Scholar 

Pishvaian MJ, Wang H, He AR et al (2020) A Phase I/II Study of Veliparib (ABT-888) in Combination with 5-Fluorouracil and Oxaliplatin in Patients with Metastatic Pancreatic Cancer. Clin Cancer Res 26:5092–5101. https://doi.org/10.1158/1078-0432.Ccr-20-1301

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yazinski SA, Zou L (2016) Functions, regulation, and therapeutic implications of the ATR checkpoint pathway. Annu Rev Genet 50:155–173. https://doi.org/10.1146/annurev-genet-121415-121658

Article  CAS  PubMed  Google Scholar 

Reaper PM, Griffiths MR, Long JM et al (2011) Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR. Nat Chem Biol 7:428–430. https://doi.org/10.1038/nchembio.573

Article  CAS  PubMed  Google Scholar 

Menezes DL, Holt J, Tang Y et al (2015) A synthetic lethal screen reveals enhanced sensitivity to ATR inhibitor treatment in mantle cell lymphoma with ATM loss-of-function. Mol Cancer Res 13:120–129. https://doi.org/10.1158/1541-7786.Mcr-14-0240

Article  CAS  PubMed  Google Scholar 

Curtin NJ (2023) Targeting the DNA damage response for cancer therapy. Biochem Soc Trans 51:207–221. https://doi.org/10.1042/bst20220681

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yap TA, O’Carrigan B, Penney MS et al (2020) Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors. J Clin Oncol 38:3195–3204. https://doi.org/10.1200/jco.19.02404

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mahdi H, Hafez N, Doroshow D et al (2021) Ceralasertib-Mediated ATR inhibition combined with olaparib in advanced cancers harboring DNA damage response and repair alterations (Olaparib Combinations). JCO Precis Oncol. https://doi.org/10.1200/po.20.00439

Article  PubMed  PubMed Central  Google Scholar 

Ring A, Kilburn LS, Pearson A et al (2023) Olaparib and Ceralasertib (AZD6738) in patients with triple-negative advanced breast cancer: results from cohort E of the plasmaMATCH trial (CRUK/15/010). Clin Cancer Res 29:4751–4759. https://doi.org/10.1158/1078-0432.Ccr-23-1696

Article  CAS  PubMed  PubMed Central  Google Scholar 

Park S, Kim YJ, Min YJ et al (2024) Biomarker-driven phase 2 umbrella trial: Clinical efficacy of olaparib monotherapy and combination with ceralasertib (AZD6738) in small cell lung cancer. Cancer 130:541–552. https://doi.org/10.1002/cncr.35059

Article  CAS  PubMed  Google Scholar 

Kwon M, Kim G, Kim R et al (2022) Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced gastric cancer. J Immunother Cancer. https://doi.org/10.1136/jitc-2022-005041

Article  PubMed  PubMed Central  Google Scholar 

Besse B, Pons-Tostivint E, Park K et al (2024) Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial. Nat Med 30:716–729. https://doi.org/10.1038/s41591-024-02808-y

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kim R, Kwon M, An M et al (2022) Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced/metastatic melanoma who have failed prior anti-PD-1 therapy. Ann Oncol 33:193–203. https://doi.org/10.1016/j.annonc.2021.10.009

Article  CAS  PubMed  Google Scholar 

Konstantinopoulos PA, Cheng SC, Lee EK et al (2024) Randomized Phase II study of gemcitabine with or without ATR inhibitor berzosertib in platinum-resistant ovarian cancer: final overall survival and biomarker analyses. JCO Precis Oncol 8:e2300635. https://doi.org/10.1200/po.23.00635